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IntrOductIOn
Hepatitis B disease is a prevalent viral disease in human. Over 
500 million people worldwide are suffering from hepatitis B and 
one million die each year because of the resulting complications, 
including chronic hepatitis, cirrhosis and hepatocellular carcinoma 
[1,2]. Infection with hepatitis B virus is an important, serious health 
problem across the world [1,3]. Iran was previously categorized as 
a country with moderate (2-8%) prevalence, but currently Iran is 
considered as a country with low (0.1-2%) prevalence of hepatitis 
B due to vaccination in the recent years [4-12]. A study obtained 
hepatitis B prevalence in Chaharmahal and Bakhtiari province, 
southwest Iran 1.3% [12]. In the regions with low prevalence, 
common age of infection is adolescence and young adulthood 
and main routes of transmission are horizontal such as sexual 
intercourse, blood transfusion and injection addiction with shared 
syringe. Anti-viral therapies, extensive vaccination projects and 
healthy ways of injection are the most fundamental routes to 
decreasing the infection rate and therefore hepatitis B-associated 
mortality [1]. Therefore, since the rate of permanent response to 
existing anti-viral medications is low, vaccine-assisted primary 
prevention and the enhancement of community’s immunity are the 
most important ways of controlling hepatitis B infection [13]. In 
Iran, hepatitis B vaccination of infants was integrated in Expanded 
Program on Immunization (EIP) since the year 1993. In addition, 
the individuals born between the years 1989 and 1993 (young 
adults) have been vaccinated by national project in the year 2008. 
Therefore, Iran’s community is dealing with three subpopulations 
with vaccination coverage for hepatitis B and different antibody 
 
levels. Subpopulation 1 (born after 1993) was vaccinated within 
national routine EIP program, subpopulation 2 (born between 
1989 and 1993) received vaccination under adult national project, 
and subpopulation 3 (born prior to 1989), whose data on immunity 
rate status is helpful for health planning. 
AIm
Therefore, the present study was conducted to determine the 
community protection by hepatitis B vaccine in adult population 
and compare vaccination coverage, HBs Ab level, and its effective 
titration among the three above-mentioned subpopulations in an 
accessible population in Iran.
mAterIAls And methOds
The present cross-sectional, analytical, population-based study 
was conducted within an eight-month period (from July, 2012 to 
February, 2013). The study population consisted of adults over 
15 years in rural and urban Chaharmahal and Bakhtiari. The 
sample size was decided to include 3000 individuals, according 
to confidence interval 95%, relative error 25%, 800000-individual 
population of the province, the number of (672535) individuals over 
15-year-old in the province, and the ra tio of the province population 
to the participants (weight: 266). Sampling method was clustering. 
The clusters were selected from all seven counties of the province 
per urban and rural population of each county (totally 50 urban 
and rural 60-individual clusters). Sample taking was initiated by 
interview team referring houses, showing identification card, and 
asking about the presence of individuals with inclusion criteria and 
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ABstrAct
Introduction: Hepatitis B vaccination has been integrated into 
National Expanded Program on Immunization in Iran since the 
year 1993 and young adult national vaccination project was 
done in 2008. So we have three subpopulations with vac­
cination coverage for hepatitis B and different antibody levels. 
Consisting of Subpopulation 1 born after 1993, subpopulation 
2 born between 1989 and 1993 and receiving vaccination under 
adult national project, and subpopulation 3 born prior to the year 
1989. 
Aim: The present study was conducted to investigate 
community protection by hepatitis B vaccine in adult population 
in an accessible population in Iran and compare vaccination 
coverage, HBs Ab level, and its effective titration among the 
three above­mentioned subpopulations. 
materials and methods: This cross­sectional study was done 
on a 3000­individual adult population from all seven counties 
of Chaharmahal and Bakhtiari province enrolled by clustering. 
After obtaining written consent and filling out a questionnaire 
of demographic data and history of hepatitis B vaccination by 
trained interviewers, necessary blood sample was taken and 
HBs Ab titration was checked. The data were analysed by 
chi­square in SPSS 19. The level of significance was considered 
as 0.05 and effective Ab titration as ≥ 10.
results: The mean age of the participants was 38.4±16.3 
years. Of the participants 48.2% had effective titration. 
For vaccination coverage, 77.4% were unvaccinated, 20% 
completely vaccinated, and 2.6% incompletely vaccinated with 
a significant association with effective titration (p<0.001). Eighty 
six percent of the subpopulation 1 and 79% of the subpopulation 
2 were completely vaccinated, with a significant difference 
in effective titration between them (p<0.001). Vaccination 
coverage was higher in men and the single but equal in cities 
and villages. The effective titration was significantly associated 
with being married and residence place (p=0.003). There was a 
significant association between effective titration and the time 
at vaccination (p<0.001). 
conclusion: Protection provided by hepatitis B vaccine in 
adult population is relatively suitable especially in the youth 
population; however, catch­up programs of the groups exposed 
to risk are recommended.
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then the questionnaire of demographic data and history of hepatitis 
B vaccination, complete or incomplete vaccination (three times or 
less), the time at vaccination, and family history of the disease was 
filled out by trained interviewers after obtaining the participants’ 
consent to enroll into the study. The inclusion criteria were being 
15 years and over and consent to participate. We used a valid 
structured questionnaire with close-ended and some open-ended 
questions related to the purposes of the study in official Persian 
language. In case of accessing vaccination card or injection 
certificate, the card or certificate was examined by the interviewer 
to remove recalling bias, and if there was no card or certificate, 
the information elicited from the individuals was relied on. Overall, 
we had 105 cases of missing data on vaccination history and 30 
missing data on HBs Ab titer. The missing data were not analysed 
and hence were not entered into denominator for calculation of 
effective vaccine titer and vaccine coverage proportion.
To determine antivirus Ab titration, Delaware kit (common Market) 
was used and Ab titration equal or higher than 10 was considered 
as effective. The study protocol holds ethics code of 90-2-6 
obtained from the ethics committee of the university. 
We analysed the data using descriptive parameters and chi-square 
in SPSS 19. The level of significance was 0.05. 
results
The mean age of the participants was 38.4±16.3 (15-90) years 
old, of whom 37% were male and 25% were single. Of the 
participants, 5.6% were born after 1993 and were already 
covered by national routine EPI (subpopulation 1), 12% were born 
between 1989 and 1993 and were already covered by national 
adult vaccination project (subpopulation 2), and 82.4% were 
born prior to 1989 (subpopulation 3). For vaccination coverage, 
77.4% were unvaccinated, 20% completely vaccinated, and 2.6% 
incompletely vaccinated. 48.2% (n: 1433) of the participants 
had titration level of over 10 (effective titration) and the rest had 
titration of under 10. [Table/Fig-1] shows the relationship between 
any three subpopulations and vaccination coverage. 86% of the 
subpopulation 1, 79% of the subpopulation 2, and 7% of the 
subpopulation 3 were completely vaccinated [Table/Fig-1].
[Table/Fig-2] shows the relationship between any three subpopu-
lations and effective titration. The highest effective titration was 
obtained in the subpopulation 2 and the least in the subpopulation 
3, with a significant difference (p<0.001) [Table/Fig-2]. [Table/
Fig-3] shows the relationship between vaccination coverage and 
effective titration. 69.3% of the completely vaccinated, 56% of 
the incompletely vaccinated, and 42% of the unvaccinated had 
effective titration. Chi-square indicated that there was a significant 
association between Ab titration and vaccination coverage 
(p<0.001). Complete vaccination coverage was 21% and 19.4% 
in men and women, 52% and 10.3% in the single and the married, 
and 19.8% and 19.5% in cities and villages, respectively. There 
was no significant association between effective titration and 
gender (48.8% in men vs. 47.9% in women, p>0.05), but the 
effective titration was significantly associated with marital status 
(58% in the single vs. 45% in the married, p<0.001). The effective 
titration was significantly associated with residence place (56% 
in the rural areas, 46% in the urban areas, and 33% in nomads, 
p=0.003). There was a significant association between effective 
titration and the time at vaccination (p<0.001), such that 77% of the 
participants with less than five years and 62% of those with more 
than five years passing since their last vaccination had a titration of 
above 10. There was no significant association between effective 
titration and contact with the infected individuals, infected first-
degree relative, smoking, blood transfusion, and breast feeding 
(p>0.05).
dIscussIOn 
Overall, 48.2% of the population had effective HBs Ab titration 
(above 10). Similar studies have been already conducted in other 
regions of Iran [14,15]. In a study of Nahavand, west Iran in the year 
2006, HBs Ab prevalence was obtained 11.6% in the population 
above 5 years, and 33.6% in 5- to 10-year-old population with 
95% coverage of hepatitis B vaccination [14]. In a study in Amol, 
north Iran in the year 2011, HBs Ab prevalence was reported 
27.9% [15]. In study of Tukat province, Turkey in the year 2009 
on a 1098-individual population, 22.8% of the participants had 
Ab [16]. In a similar study in China in the year 2010, positive Ab 
prevalence was reported 51%. In China, in addition to routine 
hepatitis B vaccination in childhood since 1992 and infants’ free 
vaccination since 2001, covering more than 99% of the 1- to 
2-year-old infants, a catch-up immunization was also conducted 
in the year 2009 for the unvaccinated or incompletely vaccinated 
children under 15 years [17]. In Singapore, immunity level in age 
group of 18-69 years was obtained 39.7% in the year 1999 and 
42% in 2005. In Singapore, a catch-up plan was conducted in 
the year 2001 for adolescents and youth population [18]. In a 
study on 1997 adult individuals in the year 2006 in Bangladesh, 
the immunity level was derived 29% [19]. In Chaharmahal and 
Bakhtiari province, because of national adult project of hepatitis 
B vaccination in the year 2008 that covered young adults (15-
18 years), partial agreement of this study’s results with China and 
Singapore studies [17,18] and higher figures compared to other 
studies [14-16] could be explained.
Vaccination status ab < 10 ab >10 
Total 
number df
p-value
(Chi 
square 
test)
Subpopulation 1
(born after 1993)
66(39%) 103(61%) 169 2 0.0001
Subpopulation 2
(born from 1989 till 
1993)
54(15.3%) 299(84.7%) 353
Subpopulation 3
(born prior to 1989)
1408(57.9%) 1026(42.1) 2434
Total 1528 1428 2956
[table/Fig-2]: Relationship between effective titration and three subpopulations of 
vaccination status.
Vaccination 
coverage ab<10 ab>10 
Total 
number df
p-value
(Chi 
square 
test)
Unvaccinated 1277(57.6%) 940(42.4%) 2217 2 0.0001
Incomplete 
vaccination
32(43.2%) 42(56.8%) 74
Complete vaccination 177(30.7%) 399(69.3%) 576
Total 1486 1381 2867
[table/Fig-3]: Relationship between vaccination coverage and effective titration
Vaccination coverage
Subpopulation 1
(born after 1993)
Subpopulation 2
(born from 1989 till 1993)
Subpopulation 3
(born prior to 1989) Total number df
p-value
Chi- square test
Unvaccinated 17(10.4%) 49(15%) 2165(91%) 2231 4 0.0001
Incomplete vaccination 6(3.6%) 21(6%) 46(2%) 73
Complete vaccination 141(86%) 274(79%) 164(7%) 579
total 164 344 2375 2883
[table/Fig-1]: Relationship between vaccination coverage and three subpopulations of vaccination status.
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there was no significant association between effective Ab titration 
and contact with the infected, first-degree relative infected with 
the virus, smoking, blood transfusion, and breast feeding, which is 
consistent with the results of other studies [20-24]. 
cOnclusIOn
Based on the results of this study and other studies, vaccination 
coverage and HBs Ab level are relatively suitable in the youth 
population of this province; however, catch-up programs and call-
out of the groups exposed to risk are recommended to increase 
coverage.
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